Oramed Pharm (ORMP) AI Stock Analysis

Top Page

Oramed Pharm

(NASDAQ:ORMP)

Select Model

Rating:63Neutral

Price Target:$4.50▲(9.49% Upside)

Action:reiterated

Date:09/18/26

Oramed Pharmaceuticals' score of 63 is anchored by a flawless balance sheet that provides exceptional runway for its clinical trials, effectively neutralizing the lack of recurring revenue. Technical indicators are largely supportive with a solid long-term trend, despite some near-term softness. The valuation is distorted by a one-time net income event, while recent corporate governance approvals reinforce shareholder confidence and management stability.

Positive Factors

Conservative balance sheetExtremely low leverage and a sizable equity base give Oramed financial flexibility relative to more indebted biotechnology peers. This reduces solvency pressure and preserves capacity to support development activities while the company works toward establishing sustainable operating performance.

Negative Factors

Minimal and inconsistent revenueLimited or zero revenue indicates that Oramed has not yet established a durable commercial operating base. This leaves financial performance dependent on development progress and future product success, while restricting internally generated resources available to fund ongoing activities.

Oramed Pharm (ORMP) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $170.97M
Dividend Yield: ―
Average Volume (3M): 181.57K
Price to Earnings (P/E): 1.0
Beta (1Y): 0.45
Revenue Growth: -100.00%
EPS Growth: ―
Country: US
Employees: 13
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Oramed Pharm Business Overview & Revenue Model

Company Description

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypep...

Oramed Pharm Financial Statement Overview

Summary

The company boasts a fortress-like balance sheet with virtually no debt and over $317 million in equity, providing an immense financial runway. This exceptional capital structure safely offsets the inherent early-stage biotech risks of zero core revenue and negative operating cash flow.

Income Statement

60Neutral

Balance Sheet

95Very Positive

Cash Flow

45Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Sep 2023	Dec 2022	Aug 2021
Income Statement
Total Revenue	0	2.00M	0	1.34M	2.70M	2.70M
Gross Profit	-91.00K	13.00K	0	1.34M	2.70M	2.70M
EBITDA	151.83M	75.44M	-14.87M	7.32M	-40.54M	-24.15M
Net Income	174.87M	64.05M	-19.06M	5.53M	-37.76M	-22.24M
Balance Sheet
Total Assets	369.64M	230.86M	155.28M	220.55M	161.64M	128.00M
Cash, Cash Equivalents and Short-Term Investments	50.61M	125.89M	141.93M	162.05M	155.72M	94.14M
Total Debt	733.00K	825.00K	372.00K	51.62M	894.00K	533.00K
Total Liabilities	52.17M	31.12M	9.93M	57.66M	10.49M	11.48M
Stockholders Equity	317.47M	199.74M	146.26M	163.82M	151.81M	115.77M
Cash Flow
Free Cash Flow	-5.37M	-11.08M	-8.43M	-10.55M	-29.20M	-21.56M
Operating Cash Flow	-5.57M	-9.14M	-8.41M	-10.29M	-28.70M	-21.18M
Investing Cash Flow	21.98M	5.44M	105.82M	-73.04M	30.21M	-22.26M
Financing Cash Flow	-16.71M	-4.74M	-52.04M	51.98M	11.56M	101.39M

Oramed Pharm Technical Analysis

Technical Analysis SentimentNegative

Last Price4.11

Price Trends

50DMA4.57Negative

100DMA4.40Negative

200DMA4.03Positive

Market Momentum

MACD-0.11Negative

RSI39.20Neutral

STOCH65.01Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Negative. The current price of 4.11 is below the 20-day moving average (MA) of 4.20, below the 50-day MA of 4.57, and above the 200-day MA of 4.03, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 39.20 is Neutral, neither overbought nor oversold. The STOCH value of 65.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORMP.

Oramed Pharm Risk Analysis

Oramed Pharm disclosed 42 risk factors in its most recent earnings report. Oramed Pharm reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Oramed Pharm Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

ORMP against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ORMP	63Neutral	$170.97M	0.97	72.96%	―	-100.00%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WHWK	44Neutral	$184.71M	-2.89	-53.89%	―	-100.00%	-1813.57%
ALXO	39Underperform	$168.70M	-1.08	-90.30%	―	―	48.20%
SPRB	31Underperform	$133.33M	-1.14	-123.53%	―	-100.00%	52.43%

* Healthcare Sector Average

Performance Comparison

ORMP and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
ORMP	Oramed Pharmaceuticals Inc	4.11	1.91	86.82%
WHWK	Whitehawk Therapeutics, Inc.	3.24	1.02	45.95%
ALXO	Alx Oncology Holdings, Inc.	1.22	-0.35	-22.29%
SPRB	Spruce Biosciences, Inc.	46.39	-58.36	-55.71%

Oramed Pharm Corporate Events

Business Operations and StrategyExecutive/Board ChangesShareholder Meetings

Oramed Pharm Shareholders Back Governance and Incentive Plan

Positive

Sep 17, 2026

At its Annual Meeting of Stockholders held on September 15, 2026, Oramed Pharm shareholders re-elected all incumbent directors to serve until the next annual meeting and ratified the appointment of Kesselman & Kesselman, a member of Pricewaterhou...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 18, 2026

Oramed Pharm AI Stock Analysis